Related Experiment Video
Updated: May 6, 2026

Using the Activity-based Anorexia Rodent Model to Study the Neurobiological Basis of Anorexia Nervosa
Published on: October 22, 2015
Changes of laboratory parameters during olanzapine treatment in young people with anorexia nervosa: exploratory
Can Xu1, Rebecca Morris1, Dominic Stringer2,3
1Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, Centre for Research in Eating and Weight Disorders (CREW), London, UK.
Background:
While olanzapine is recommended for promoting weight recovery in adults with anorexia nervosa (AN), its use in young people remains under-researched, necessitating the careful monitoring of blood-based laboratory parameters to manage the potential side effects of olanzapine.
Methods:
In the OPEN feasibility study which tested olanzapine treatment over 6 months in young people with AN, 15 study participants (aged 12-23) adhered to olanzapine treatment for at least 16 weeks and had clinical blood-based laboratory parameters measured.
Results:
In an exploratory analysis, we found a mean increase of 0.06 x 109/L in white blood cell count (WBC) (0.01, 0.11 95% CI) per week. Bilirubin decreased by 0.11 mg/dL (-0.19, -0.04 95% CI) per week, and serum albumin levels dropped slightly by 0.20 g/L (-0.29, -0.11 95% CI) per week. Electrolytes, liver enzymes, total cholesterol and triglycerides remained stable during treatment with olanzapine.
Conclusions:
Whereas the increase in WBC and the decrease in bilirubin likely reflect nutritional rehabilitation, the reason for the albumin reduction is unclear. Thus, monitoring serum albumin during trials and clinical treatment for AN with olanzapine is advised.
More Related Videos
Related Concept Videos
Bioavailability Study Design: Healthy Subjects Versus Patients
Psychosis: Goals of Pharmacotherapy
Antipsychotic Drugs: Typical and Atypical Agents
Anorexia Nervosa
Symptoms and Physical Effects
Individuals with anorexia nervosa commonly exhibit extreme...
Therapeutic Drug Monitoring: Affecting Factors
Mania and Antimanic Drugs: Overview

